S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
NASDAQ:ZLAB

Zai Lab (ZLAB) Stock Price, News & Analysis

$16.19
+0.24 (+1.50%)
(As of 03/27/2024 ET)
Today's Range
$15.71
$16.65
50-Day Range
$15.95
$23.56
52-Week Range
$15.69
$40.42
Volume
1.04 million shs
Average Volume
614,774 shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.22

Zai Lab MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
296.7% Upside
$64.22 Price Target
Short Interest
Healthy
3.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Zai Lab in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$776,112 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.10) to ($1.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.52 out of 5 stars

Medical Sector

489th out of 939 stocks

Pharmaceutical Preparations Industry

229th out of 435 stocks

ZLAB stock logo

About Zai Lab Stock (NASDAQ:ZLAB)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Stock Price History

ZLAB Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
ZLAB Sep 2024 17.500 call
ZLAB Jan 2025 20.000 call
Zai Lab (NASDAQ:ZLAB) Shares Gap Down to $17.25
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Shhh! 7 Small-Cap Stocks That Can Double by 2025
ZLAB Apr 2024 12.500 put
ZLAB Apr 2024 25.000 call
ZLAB Apr 2024 17.500 call
ZLAB Apr 2024 17.500 put
ZLAB Apr 2024 22.500 call
ZLAB Apr 2024 20.000 put
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZLAB
Employees
2,175
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$64.22
High Stock Price Target
$73.34
Low Stock Price Target
$47.50
Potential Upside/Downside
+296.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-334,620,000.00
Net Margins
-125.46%
Pretax Margin
-125.46%

Debt

Sales & Book Value

Annual Sales
$266.72 million
Book Value
$8.05 per share

Miscellaneous

Free Float
93,670,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
1.13
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives


ZLAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings
or view top-rated stocks.

What is Zai Lab's stock price target for 2024?

5 equities research analysts have issued 12-month target prices for Zai Lab's stock. Their ZLAB share price targets range from $47.50 to $73.34. On average, they anticipate the company's stock price to reach $64.22 in the next twelve months. This suggests a possible upside of 296.7% from the stock's current price.
View analysts price targets for ZLAB
or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2024?

Zai Lab's stock was trading at $27.33 at the beginning of the year. Since then, ZLAB shares have decreased by 40.8% and is now trading at $16.19.
View the best growth stocks for 2024 here
.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ZLAB earnings forecast
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) released its earnings results on Tuesday, February, 27th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.87) by $0.11. The business earned $65.83 million during the quarter, compared to analyst estimates of $70.41 million. Zai Lab had a negative trailing twelve-month return on equity of 37.07% and a negative net margin of 125.46%.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

Zai Lab (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.40%), Price T Rowe Associates Inc. MD (2.74%), Price T Rowe Associates Inc. MD (2.74%), Viking Global Investors LP (1.89%), Segantii Capital Management Ltd (1.71%) and Legal & General Group Plc (0.84%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Peter Wirth, Rafael Amado, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZLAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners